KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to -$8.7 million.

  • AbCellera Biologics' Net Cash Flow rose 6037.03% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.1 million, marking a year-over-year increase of 919.12%. This contributed to the annual value of $25.6 million for FY2024, which is 11006.25% up from last year.
  • Per AbCellera Biologics' latest filing, its Net Cash Flow stood at -$8.7 million for Q3 2025, which was up 6037.03% from -$67.6 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Net Cash Flow peaked at $247.0 million during Q2 2022, and registered a low of -$408.8 million during Q3 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$8.7 million (2025), whereas its average is -$24.8 million.
  • The largest annual percentage gain for AbCellera Biologics' Net Cash Flow in the last 5 years was 34217.34% (2021), contrasted with its biggest fall of 114528.47% (2021).
  • AbCellera Biologics' Net Cash Flow (Quarter) stood at -$16.0 million in 2021, then soared by 188.59% to $14.2 million in 2022, then tumbled by 382.92% to -$40.2 million in 2023, then soared by 179.28% to $31.8 million in 2024, then plummeted by 127.43% to -$8.7 million in 2025.
  • Its last three reported values are -$8.7 million in Q3 2025, -$67.6 million for Q2 2025, and $2.4 million during Q1 2025.